Literature DB >> 1831058

Specific binding sites for H-ferritin on human lymphocytes: modulation during cellular proliferation and potential implication in cell growth control.

S Fargion1, A L Fracanzani, B Brando, P Arosio, S Levi, G Fiorelli.   

Abstract

Interactions between human recombinant H- and L-ferritins and human lymphocytes were studied in vitro by direct binding assays and by flow cytometry. L-ferritin did not cause detectable specific binding, whereas H-ferritin showed a specific and saturable binding that increased markedly in phytohemagglutinin (PHA)-stimulated cells. This ferritin bound up to 30% of CD4+ and CD8+ T-lymphocytes and most B cells, indicating that expression of ferritin binding sites is not related to cell lineage or function. Dual-color flow cytometry experiments showed that ferritin binding sites were present on cells expressing the proliferation markers HLA-DR, MLR3, interleukin 2 (IL-2), and transferrin receptors (Tf-R). In addition, after PHA induction, the time course of the expression of H-ferritin binding sites was similar to those of the above proliferation markers. Ferritin binding sites were observed in lymphocytes at all cell cycle phases, including the early S-phase. H-Ferritin at nanomolar and picomolar concentrations had an inhibitory effect on PHA-induced blastogenesis. We propose that H-ferritin binding sites behave like proliferation markers, with the unusual function of downregulating proliferation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831058

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Sequence, structure, function, immunity: structural genomics of costimulation.

Authors:  Kausik Chattopadhyay; Eszter Lazar-Molnar; Qingrong Yan; Rotem Rubinstein; Chenyang Zhan; Vladimir Vigdorovich; Udupi A Ramagopal; Jeffrey Bonanno; Stanley G Nathenson; Steven C Almo
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

2.  Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.

Authors:  A Alkhateeb; L Zubritsky; B Kinsman; K Leitzel; C Campbell-Baird; S M Ali; J Connor; A Lipton
Journal:  J Gastrointest Cancer       Date:  2014-06

Review 3.  The role of iron and iron binding proteins in lymphocyte physiology and pathology.

Authors:  J D Kemp
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

4.  Identification and characterization of a receptor for tissue ferritin on activated rat lipocytes.

Authors:  G A Ramm; R S Britton; R O'Neill; B R Bacon
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

Review 5.  Hyperferritinemia and inflammation.

Authors:  Kate F Kernan; Joseph A Carcillo
Journal:  Int Immunol       Date:  2017-11-01       Impact factor: 4.823

Review 6.  Serum ferritin: Past, present and future.

Authors:  Wei Wang; Mary Ann Knovich; Lan G Coffman; Frank M Torti; Suzy V Torti
Journal:  Biochim Biophys Acta       Date:  2010-03-19

7.  Denatured H-ferritin subunit is a major constituent of haemosiderin in the liver of patients with iron overload.

Authors:  E Miyazaki; J Kato; M Kobune; K Okumura; K Sasaki; N Shintani; P Arosio; Y Niitsu
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

8.  The immunosuppressive human placental ferritin subunit p43 is produced by activated CD4+ lymphocytes.

Authors:  B Garty; E Kaminsky; C Moroz
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

9.  Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS.

Authors:  Simon Swingler; Jin Zhou; Catherine Swingler; Ann Dauphin; Thomas Greenough; Paul Jolicoeur; Mario Stevenson
Journal:  Cell Host Microbe       Date:  2008-07-17       Impact factor: 21.023

10.  Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver.

Authors:  Paola Dongiovanni; Luca Valenti; Anna Ludovica Fracanzani; Stefano Gatti; Gaetano Cairo; Silvia Fargion
Journal:  Am J Pathol       Date:  2008-02-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.